Factors Associated with Drug Survival of Methotrexate and Acitretin in Patients with Psoriasis
DOI:
https://doi.org/10.2340/00015555-2130Keywords:
psoriasis, drug survival, traditional systemic agents, folic acid, metho-trexate, acitretin.Abstract
Drug survival has recently become an important clinical issue in psoriasis. However, there has been little research into factors associated with drug survival of methotrexate and acitretin. The aim of this study was to investigate factors associated with drug survival of methotrexate and acitretin treatment for psoriasis. Survival analysis was performed in patients who received methotrexate or acitretin for the treatment of psoriasis, drawn from the Clalit Health Services database. Investigated factors included demographic variables, obesity, metabolic syndrome, psoriatic arthritis, administration route and folic acid supplementation. Among 6,256 patients, factors associated with treatment drop-out were: younger age (p<0.001) and psoriatic arthritis (acitretin p<0.001). For methotrexate, metabolic syndrome (p=0.033), intramuscular administration route of injection (p<0.001) and lack of folic acid supplementation (p<0.001) were associated with treatment drop-out. In patients with psoriasis, some ancillary factors may modify the drug survival of acitretin and methotrexate.Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Guy Shalom, Devy Zisman, Ilana Harman-Boehm, Haim Biterman, Sari Greenberg-Dotan, Ilya Polishchuk, Hadas Moser, Tamar Freud, Ilan Feldhamer, Arnon D. Cohen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
